- Home
- HURA vs HUMA Comparison
HURA vs HUMA Comparison
Compare HURA & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HURA | HUMA |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5M | 191.4M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HURA | HUMA |
|---|---|---|
| Price | $2.22 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $9.50 | $6.19 |
| AVG Volume (30 Days) | 251.5K | ★ 7.9M |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 47.93 | ★ 79.37 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | N/A | $444.16 |
| Revenue Next Year | N/A | $248.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.53 |
| 52 Week High | $3.43 | $2.55 |
Technical Indicators
Market Signals| Indicator | HURA | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 50.05 |
| Support Level | $2.11 | $0.61 |
| Resistance Level | $2.59 | $0.75 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 31.81 | 68.31 |
Price Performance
Historical ComparisonAbout HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.